Brief: Protalix Biotherapeutics Reports First Quarter 2023 Financial And Business Results
04/05/2023 12:17
Protalix Biotherapeutics Inc PBDA.F :
* PROTALIX BIOTHERAPEUTICS REPORTS FIRST QUARTER 2023
FINANCIAL
AND BUSINESS RESULTS
* PROTALIX BIOTHERAPEUTICS INC- QTRLY LOSS PER SHARE $0.05
* PROTALIX BIOTHERAPEUTICS INC - CASH AND CASH EQUIVALENTS
WERE
APPROXIMATELY $33.0 MILLION AT MARCH 31, 2023
Source text for Eikon: ID:nPnPFyvqa
Further company coverage: PBDA.F
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio